ArticleACS applied materials & interfaces2018
A Universal GSH-Responsive Nanoplatform for the Delivery of DNA, mRNA, and Cas9/sgRNA Ribonucleoprotein.
Article in ACS applied materials & interfaces, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Stimuli-responsive nanocarriers for targeted mRNA therapeutics: a paradigm shift in mRNA delivery for biomedical applications.Drug delivery and translational research · 2026Review
- Nature Inspired Delivery Vehicles for CRISPR-Based Genome Editing.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- The mRNA-Based Innovative Strategy: Progress and Challenges.Nano-micro letters · 2026Review
- Precisely Targeted Nanoparticles for CRISPR-Cas9 Delivery in Clinical Applications.Nanomaterials (Basel, Switzerland) · 2025Review
- Glutathione-responsive Nanoparticles for Optimized Cas9/sgRNA Gene Editing Delivery.Current drug targets · 2025Article
- Recent advances in the development of poly(ester amide)s-based carriers for drug delivery.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Review
- Nanoparticle technology for mRNA: Delivery strategy, clinical application and developmental landscape.Theranostics · 2024Review
- Delivery of mRNA with Histidine-Lysine Peptides.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Current State of Human Gene Therapy: Approved Products and Vectors.Pharmaceuticals (Basel, Switzerland) · 2023Review
- mRNA nanodelivery systems: targeting strategies and administration routes.Biomaterials research · 2023Review
- Nano-engineering nanomedicines with customized functions for tumor treatment applications.Journal of nanobiotechnology · 2023Review
- Polymer-Based mRNA Delivery Strategies for Advanced Therapies.Advanced healthcare materials · 2023Review
- mRNA-based modalities for infectious disease management.Nano research · 2023Review
- Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing.Journal of nanobiotechnology · 2022Review
- Polymeric Micelles with pH-Responsive Cross-Linked Core Enhance In Vivo mRNA Delivery.Pharmaceutics · 2022Article
- Nano-vectors for CRISPR/Cas9-Mediated Genome Editing.Nano today · 2022Article
- Carrier strategies boost the application of CRISPR/Cas system in gene therapy.Exploration (Beijing, China) · 2022Review
- Applications and developments of gene therapy drug delivery systems for genetic diseases.Asian journal of pharmaceutical sciences · 2021Review
- External stimuli-responsive nanoparticles for spatially and temporally controlled delivery of CRISPR-Cas genome editors.Biomaterials science · 2021Review
- Disulfide Bridging Strategies in Viral and Nonviral Platforms for Nucleic Acid Delivery.Biochemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The long-sought promise of gene therapy for the treatment of human diseases remains unfulfilled, largely hindered by the lack of an efficient and safe delivery vehicle. In this study, we have developed a universal glutathione-responsive nanoplatform for the efficient delivery of negatively charged genetic biomacromolecules. The cationic block copolymer, poly(aspartic acid-(2-aminoethyl disulfide)-(4-imidazolecarboxylic acid))-poly(ethylene glycol), bearing imidazole residues and disulfide bonds, can form polyplexes with negatively charged DNA, mRNA, and Cas9/sgRNA ribonucleoprotein (RNP) through electrostatic interactions, which enable efficient cellular uptake, endosomal escape, and cytosol unpacking of the payloads. To facilitate the nuclear transport of DNA and RNP, the nuclear localization signal peptide was integrated into the DNA or RNP polyplexes. All three polyplex systems were fully characterized and optimized in vitro. Their relatively high transfection efficiency and low cytotoxicity, as well as convenient surface functionalization merit further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.